Powering the next wave of genetic medicines through superior delivery
First genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver
Precision Genetic Medicines
Pipeline of rare disease therapeutics using optimized mRNA and gene correction with redosing capability
Vast Expansion Potential
Unique platform properties enable the packaging and delivery of a wide range of genetic medicine cargoes via multiple routes of administration
ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform
The SORT LNP platform is a first-in-class modular genetic medicines technology that goes beyond the lipid delivery system used by the mRNA COVID-19 vaccines. Our platform is engineered to deliver the right genetic therapeutic to the right organs and tissues with the optimal mode of administration.
A New Era of Possibility for Genetic Medicines
ReCode’s technology has potential to transcend the limitations of current genetic medicine delivery systems so that people with rare diseases may fully benefit from disease-modifying, corrective therapeutics
“At ReCode, I have the rare opportunity to drive a seismic shift for genetic medicines and make a meaningful difference for patients with rare diseases.”
ReCode Your Future
We’re seeking teammates who see unlimited potential in themselves and the future of genetic medicine.